Orpadrex
Every registration of this product has been cancelled.
N,N-Dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 4601.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| The Premier Pharmaceutical Co LtdCancelled | Orpadrex | Not stated | C0675 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Orpadrex TABLET ORPHENADRINE HYDROCHLORIDE A 50 MG | Not listed | C0675 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Orphenadrine
- except when contained in preparations intended for use as a muscle relaxant.
Consolidated Schedules 06 July 2026, line 7407
S2: Orphenadrine
- when contained in preparations intended for use as a muscle relaxant.
Consolidated Schedules 06 July 2026, line 2468
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.